Business / Finance RSS Feed - Business / Finance

Cambridge Consultants creates new Evonetix spin-out to focus on accurate DNA synthesis

Cambridge Consultants creates new Evonetix spin-out to focus on accurate DNA synthesis

A breakthrough in DNA synthesis has led to the creation of a new spin-out company from the stable of product design and development firm Cambridge Consultants. [More]
CSIRO's partner Oventus Medical listed on ASX after raising $12 million

CSIRO's partner Oventus Medical listed on ASX after raising $12 million

CSIRO partner Oventus Medical Ltd has today listed on the Australian Securities Exchange raising $12m. [More]
KNAUER named among TOP 100 innovative medium-sized businesses in Germany for fifth time

KNAUER named among TOP 100 innovative medium-sized businesses in Germany for fifth time

During the 3rd German Summit for medium-sized businesses at UNESCO World Heritage Zeche Zollverein in Essen, mentor Ranga Yogeshwar awarded this year’s Top-Innovators on June 24. [More]
Opioid funding bill should address greater access to balanced pain management

Opioid funding bill should address greater access to balanced pain management

The Alliance for Balanced Pain Management (AfBPM) made the following statement on the Obama administration’s plan to curb the opioid addiction crisis, which was released this morning as Congress prepares to tackle funding for related programs. [More]
Osprey Medical announces record sales for medical device

Osprey Medical announces record sales for medical device

Osprey Medical has announced record sales results for the second quarter of CY2016, reflecting strong adoption by physicians and hospitals of Osprey’s technology protecting patients from the harmful effects of X-ray dye. [More]
Minoryx Therapeutics initiates phase 1 clinical trial of MIN-102

Minoryx Therapeutics initiates phase 1 clinical trial of MIN-102

Minoryx Therapeutics, a drug development company specialized in the discovery and development of new drugs for orphan diseases, today announces the initiation of its first-in-man Phase 1 clinical trial for its lead compound MIN-102. [More]
RedHill Biopharma and IntelGenx announce definitive agreement for commercialization of RIZAPORT™ for migraines with Grupo JUSTE in Spain and additional potential territories

RedHill Biopharma and IntelGenx announce definitive agreement for commercialization of RIZAPORT™ for migraines with Grupo JUSTE in Spain and additional potential territories

RedHill Biopharma Ltd., a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases and cancer, together with IntelGenx Corp., a Canadian drug delivery company focused on oral drug delivery, today announced the signing of an exclusive license agreement with Grupo JUSTE S.A.Q.F (“Grupo JUSTE”), for the commercialization of RIZAPORT™ in Spain, and a right of first refusal for additional territories. RIZAPORT™ is a proprietary oral thin film formulation of rizatriptan for the treatment of acute migraines. [More]

BioTek Instruments expands in Canada

BioTek Instruments, Inc. affirms their ongoing investment across the North American microplate-based technology market with the expansion of their business in Canada. The dedicated sales and support operation will focus on bringing enhanced applications and technical support throughout the country. [More]
MorphoSys receives clinical milestone for start of Phase 1 trial in prevention of thrombosis with novel antibody

MorphoSys receives clinical milestone for start of Phase 1 trial in prevention of thrombosis with novel antibody

MorphoSys AG announced that it has received a milestone payment from Novartis in connection with the initiation of a clinical phase 1 trial with a novel HuCAL antibody. The antibody will be tested in the field of prevention of thrombosis. This is the twelfth therapeutic antibody based on MorphoSys's technologies that Novartis is evaluating in clinical trials. Financial details were not disclosed. [More]
Alnylam reports new results from investigational RNAi therapeutic programs

Alnylam reports new results from investigational RNAi therapeutic programs

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today preliminary results from its ongoing Phase 2 open-label extension (OLE) studies with patisiran and revusiran, both investigational RNAi therapeutics targeting transthyretin (TTR) for the treatment of hereditary TTR-mediated amyloidosis (hATTR amyloidosis). [More]
CDC invests in Donator’s unique heat stabilization technology

CDC invests in Donator’s unique heat stabilization technology

Denator, the Swedish-based biotechnology company specialized in biological sample preparation technologies announced today that the Center for Disease Control and Prevention, Atlanta, had made a major purchase of its proprietary heat stabilization technology Stabilizor T1™. [More]
Quantum Genomics initiates Phase IIa trial for heart failure

Quantum Genomics initiates Phase IIa trial for heart failure

Quantum Genomics, a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, today announced the initiation of its Phase IIa multicentric clinical trial of GQC101, entitled QUID HF (QUantum Genomics Incremental Dosing in Heart Failure), for the treatment of patients with chronic heart failure. The first three clinical centres of the European trial have been opened in France and Norway. [More]
Proscia completes $1M seed round of financing to advance cancer diagnosis, treatment

Proscia completes $1M seed round of financing to advance cancer diagnosis, treatment

Proscia Inc., a data solutions provider for digital pathology, announced today the completion of its $1M seed round of financing. [More]
Illumina signs initial customer deals for new Global Screening Array

Illumina signs initial customer deals for new Global Screening Array

Illumina, Inc. today announced that it has signed deals with 12 customers for its new Infinium Global Screening Array (GSA). [More]
David Gandy becomes new ambassador for Vitabiotics Wellman

David Gandy becomes new ambassador for Vitabiotics Wellman

Known for his passion for fitness and for the championing of top British brands, David Gandy is the new ambassador for Vitabiotics Wellman. [More]
TxCell, LIED collaborate to develop CAR-Treg-based cellular immunotherapy for bullous pemphigoid

TxCell, LIED collaborate to develop CAR-Treg-based cellular immunotherapy for bullous pemphigoid

TxCell SA, a biotechnology company developing innovative, personalized cellular immunotherapies using regulatory T cells to treat severe chronic inflammatory and autoimmune diseases, today announces the signature of a strategic R&D collaboration agreement with the Lübeck Institute of Experimental Dermatology, a leading institution in the field of translational research on skin blistering diseases, part of the University of Lübeck in Germany. [More]
New £95 million investment in pathology services set to bring major benefits to millions of patients

New £95 million investment in pathology services set to bring major benefits to millions of patients

A new £95 million investment in laboratory testing and diagnostic services at Central Manchester University Hospitals NHS Foundation Trust will make a major impact on the wide range of general and specialist services provided to CMFT patients who come from all over the Greater Manchester region and beyond. [More]
Bifodan announces expansion of global operations

Bifodan announces expansion of global operations

Bifodan, a distinct provider of probiotic solutions for the private label nutritional industry, announces a significant expansion of its global operations. [More]
ProBioGen will license GlymaxX® to Thermo Fisher Scientific for use in developing allergy diagnostics

ProBioGen will license GlymaxX® to Thermo Fisher Scientific for use in developing allergy diagnostics

ProBioGen, a leading specialist for contract development and manufacturing of complex glycoproteins and corresponding technologies, today announced that Thermo Fisher Scientific has licensed its GlymaxX® technology for use in development of allergy diagnostics. [More]
Mazor Robotics signs strategic commercial and investment agreements with Medtronic

Mazor Robotics signs strategic commercial and investment agreements with Medtronic

Mazor Robotics Ltd., a leading developer of innovative bone mounted surgical robotic guidance systems, today entered into two strategic agreements with Medtronic plc (NYSE: MDT). One agreement is a two-stage, multi-faceted, commercial agreement for co-promotion, co-development and, upon meeting certain milestones, potential global distribution of certain Mazor products. The second agreement is for an equity investment by Medtronic in Mazor. [More]
Advertisement
Advertisement